Gel-One
Seikagaku Corp. · Decision date Sep 4, 2026
What did the FDA approve?
FDA recorded an approval decision on 2026-09-04 for PMA supplement P080020/S056, associated with Gel-One (Seikagaku Corp.). The supplement was filed under the 135 Review Track for 30-Day Notice with a recorded reason of Process Change - Manufacturer/Sterilizer/Packager/Supplier. The device category is listed as acid, hyaluronic, intraarticular, with orthopedic specialty and product code MOZ.
The recorded scope is limited to manufacturing: replacing one of two existing isolators used for sterility testing of Gel-One with a new isolator that has an integrated hydrogen peroxide decontamination system. This is a supplement-level decision about that equipment change, not a new approval of the Gel-One device or its clinical use. The source record does not include the supplement documents, so the review basis and any conditions tied to the isolator change remain unknown.
FDA approval order statement
Approval to replace one of two existing isolators used for sterility testing of Gel-One with a new isolator equipped with an integrated hydrogen peroxide decontamination system.
- Regulatory pathway
- PMA supplement
- Supplement type
- 135 Review Track For 30-Day Notice
- Clinical specialty
- Orthopedic
- Decision date
- Sep 4, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P080020/S056
- Regulatory pathway
- PMA supplement
- Applicant
- Seikagaku Corp.
- Product code
- MOZ
- Decision code
- APPR
- Decision date
- Sep 4, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Acid, hyaluronic, intraarticular.
- Applicant
- Seikagaku Corp.
- Product code
- MOZ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P080020. Subsequent supplements may change the device or its indications.
FDA decision timeline
P080020 · Original PMA
GEL-ONE
P080020/S056 received
Application receipt date recorded by FDA.
P080020/S056 · FDA decision
135 Review Track For 30-Day Notice
Timeline entries are records held by MedtechLedger for P080020. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P080020
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
GEL-ONEP080020 | Seikagaku Corp. | PMA approval | Mar 22, 2011 | FDA |
GEL-ONEP080020/S055 | Seikagaku Corp. | PMA supplement | Apr 9, 2026 | FDA |
GEL-ONEP080020/S057 | Seikagaku Corp. | PMA supplement | Aug 26, 2026 | FDA |
Explore the linked device profile
Other records with product code MOZ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
SUPARTZ FXP980044/S067 | Seikagaku Corp. | PMA supplement | Sep 4, 2026 | FDA |
EUFLEXXA (1% sodium hyaluronate)P010029/S043 | Ferring Pharmaceuticals, Inc. | PMA supplement | Sep 2, 2026 | FDA |
Orthovisc Injectable Intra-Articular DevicesP030019/S028 | Anika Therapeutics, Inc. | PMA supplement | Aug 28, 2026 | FDA |
SUPARTZ FXP980044/S068 | Seikagaku Corp. | PMA supplement | Aug 26, 2026 | FDA |
Gelsyn-3P110005/S015 | Ibsa Institut Biochimique SA | PMA supplement | Jul 24, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Seikagaku Corp.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6-1, Marunouchi 1-Chome,, Chiyoda-Ku, Tokyo, 100-0005
Sources and methodology
- Original FDA record: P080020/S056
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


